FAT1 and gastric adenocarcinoma: It was found that FAT mutations had significantly better PFS (median: 55.4 vs. 33.5 month, HR = 0.65 [95% CI, 0.47–0.92], P = 0.019) and OS (median: 55.4 vs. 25.7 month, HR = 0.71 [95% CI, 0.52–0.96], P = 0.034) compared with those without mutations (Figure 2A); thus, FAT mutations were a positive prognostic factor for patients with STAD.